Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women

NCT ID: NCT05604222

Last Updated: 2025-05-13

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-05
• Study Completion Date: 2027-03-31

Brief Summary

Urgency urinary incontinence (UUI) is common in older people and vastly reduces quality of life, yet the cause and mechanism of disease are not well understood. This study will investigate the role of adding behavioral sleep intervention to the standard pharmacotherapy in treatment of UUI among older adults, and the brain mechanisms involved in continence by evaluating brain changes. This will expand the current knowledge of how the sleep affects bladder control, and better characterize the brain mechanisms in maintaining continence.

Detailed Description

Urgency urinary incontinence (UUI), a form of overactive bladder (OAB), is prevalent (36% of women over age 65), morbid and costly ($83 billion/year), and treatment is problematic. Current treatment is largely bladder centric has limited efficacy,and adherence rates fade to 21% at 12 months. The researchers believe that a complimentary approach, one that also addresses etiology beyond the bladder may enhance treatment success. Up to 50% of older adults complain of poor sleep and nighttime bladder symptoms (nocturia) are considered the major cause. However, the relationship between sleep and the bladder is complex and bidirectional. Poor sleep not only exacerbates daytime lower urinary tract symptoms (LUTS), but can also cause these, increasing the risk of LUTS by up to 55% over 5 years. Sleep disruption increases anxiety and impairs daytime attention, both of which affect bladder control. Consistent with findings in anxiety disorders and attention control, poor sleep is linked to media prefrontal cortex (mPFC) hypoactivity, a region the investigators have identified as key to executive control of voiding and to therapeutic response to biofeedback-assisted pelvic floor muscle therapy. Hence, the investigators posit that enhanced mPFC function through improved sleep might ameliorate bladder control. Despite evidence of a bidirectional relationship, the impact of sleep treatment on UUI has never been assessed. The researchers prior study demonstrated that improving sleep using Brief Behavioral Treatment of Insomnia (BBTI), a simple intervention for insomnia, improved both sleep and nocturia in older adults, yet its impact on UUI and mechanism of action is not known. Our exploratory analysis of sleep and voiding data from 20 older adults with UUI and nocturia showed that with behavioral sleep intervention alone, 24-hour UUI episodes decreased with prolongation of uninterrupted sleep before the first awakening to void (r=-0.50, p=0.02), and increased proportion of deep sleep (r=-0.56, p=0.01). Hence, the researchers postulate that addressing sleep in patients with UUI and nocturia may further potentiate bladder-focused UUI treatment. The efficacy of mirabegron, a β3- adrenoceptor agonist is comparable to first-line antimuscarinic pharmacotherapy for UUI, with fewer side effects, but it has only a modest effect on nocturia. Although these drugs show statistically significant improvement in LUTS, drug compliance remains poor secondary to modest perceived clinical benefit. The researchers central hypothesis is that comorbid insomnia contributes to poor therapeutic response for UUI and concurrent insomnia treatment will improve outcomes. Specifically, addition of BBTI to drug therapy will improve sleep, nocturia, and daytime LUTS, likely mediated by improvement of mPFC function.

The researchers propose an 8-week randomized controlled trial of mirabegron+BBTI vs. mirabegron alone for UUI in 100 women (aged ≥60), assessing both clinical and neural effects of treatment. The researchers will also assess durability of the combination therapy at 6 months. This design encompasses the role of sleep in OAB treatment, insight into the central and peripheral effects of mirabegron and BBTI, and response durability.

Conditions

Urgency Urinary Incontinence; Nocturia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Mirabegron

Mirabegron for 8 weeks

Group Type: EXPERIMENTAL

Mirabegron 50 MG

Intervention Type: DRUG

Medication to treat overactive bladder

Mirabegron plus Brief Behavioral Treatment for Insomnia (BBTI)

Mirabegron for 8 weeks and a 4 week behavioral intervention for insomnia

Group Type: EXPERIMENTAL

Mirabegron 50 MG

Intervention Type: DRUG

Medication to treat overactive bladder

Brief Behavioral Treatment for Insomnia

Intervention Type: BEHAVIORAL

A behavioral intervention for insomnia

Interventions

Mirabegron 50 MG

Medication to treat overactive bladder

Intervention Type: DRUG

Brief Behavioral Treatment for Insomnia

A behavioral intervention for insomnia

Intervention Type: BEHAVIORAL

Other Intervention Names

Myrbetriq; BBTI

Eligibility Criteria

Inclusion Criteria

• ambulatory women aged 60+ years
• urgency incontinence or urge-predominant mixed incontinence (able to differentiate between stress symptoms-cough, laugh, exercise-and leakage following the sudden onset of a strong urge to void that is difficult to defer during questioning on telephone screening) occurring at least five times weekly for ≥ 3 months despite treatment for reversible causes
• nocturia ≥2 each night
• subjects with current or previous use of anticholinergic medications will be considered for the study if willing to go through a washout period of at least 4 weeks of duration

Exclusion Criteria

• contraindication to any of the drugs used (e.g., mirabegron, prophylactic antibiotics)
• cognitive impairment (MOCA score <24 or inability to accurately complete a voiding diary, perform a 24-hour pad test, reliably take daily medication, or comply with fMRI testing)
• prior treatment with intradetrusor onabotulinum toxin or sacral neuromodulation.
• spinal cord injury; history of pelvic irradiation, advanced uterine or bladder cancer; multiple sclerosis
• urethral obstruction; urinary retention [PVR >200 ml]
• interstitial cystitis; artificial sphincter implant
• medical instability or expected change in medication during the study
• conditions that preclude fMRI testing, such as history of claustrophobia, history or suspicion of implanted metal or electronic object
• requirement for intravenous antibiotics for bacterial endocarditis prophylaxis or presence of multiple allergies to the antibiotics available in our protocol
• chronic or recurrent bowel issues, e.g. IBS, colitis, fecal incontinence
• known allergy to study medication or interaction with current medications
• severe uncontrolled hypertension >180 mmHg systolic or >100 mmHg diastolic

• Minimum Eligible Age: 60 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

National Institute on Aging (NIA)

NIH

Sponsor Role: collaborator

Shachi Tyagi

OTHER

Sponsor Role: lead

Responsible Party

Shachi Tyagi

Assistant Professor of Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Shachi Tyagi, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Shachi Tyagi, MD

Role: CONTACT

tyagis@upmc.edu

412-647-1274

Facility Contacts

Shachi Tyagi, MD, MS

Role: primary

sht55@pitt.edu

412.647.1274

Kandy L Newell, RN

Role: backup

kln40@pitt.edu

412.647.1271

Other Identifiers

1R01AG076575-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

STUDY22050099

Identifier Type: -

Identifier Source: org_study_id